Suppr超能文献

腺苷诱发无肺部疾病患者严重支气管痉挛。

Adenosine-induced severe bronchospasm in a patient without pulmonary disease.

机构信息

Cardiology Unit, Department of Cardiology, Nephrology and Pneumology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.

出版信息

Am J Emerg Med. 2012 Nov;30(9):2082.e3-5. doi: 10.1016/j.ajem.2011.11.005. Epub 2011 Dec 15.

Abstract

Adenosine is widely used for the treatment of supraventricular tachycardias for its efficacy and excellent safety, but it has been reported to precipitate severe bronchospasm in patients with pulmonary disease. The drug is therefore contraindicated in asthmatic subjects and should be used with caution in patients with chronic obstructive pulmonary disease. Nevertheless, true bronchospasm is rare and should be distinguished from the much more common occurrence of dyspnea, only as a symptom and without respiratory compromise, which is benign and transient. We describe the occurrence of severe bronchospasm following adenosine administration for a supraventricular tachycardia in a young male without any history of pulmonary disease. To our knowledge, this is the first time such complication is reported in a subject without lung disease. The patient arrived at the emergency department for palpitations with a regular wide QRS tachycardia with a left bundle-branch block morphology. Sinus carotid massage was unsuccessful, and 2 intravenous adenosine boluses were given without effect. A further 12-mg bolus cardioverted the patient, who became increasingly dyspneic and hypoxic, with diffuse bronchospasm. An urgent chest radiograph had normal results. He was treated with oxygen and inhaled and intravenous steroids, but dyspnea and bronchospasm resolved only after intravenous aminophylline. The arrhythmia recurred and was finally terminated by intravenous flecainide. Although dyspnea after adenosine administration is usually a transient, benign phenomenon, physicians should be alert to the presence of objective signs of respiratory distress, which should prompt immediate treatment, even in subjects without previous history of pulmonary disease.

摘要

腺苷因其疗效确切和安全性好而被广泛用于治疗室上性心动过速,但有报道称其可诱发肺部疾病患者出现严重支气管痉挛。因此,该药禁用于哮喘患者,且应谨慎用于慢性阻塞性肺疾病患者。然而,真正的支气管痉挛很少见,应与更为常见的呼吸困难区分开来,后者仅作为一种症状出现,且不伴有呼吸功能障碍,是良性且短暂的。我们描述了一例年轻男性在无肺部疾病史的情况下,因室上性心动过速给予腺苷后发生严重支气管痉挛的情况。据我们所知,这是首例在无肺部疾病的患者中报告此类并发症的病例。该患者因心悸就诊,心电图显示宽 QRS 心动过速,伴左束支传导阻滞形态。颈动脉窦按摩无效,先后给予 2 次静脉推注腺苷也无效。随后给予 12mg 腺苷推注转复了患者的心律失常,但患者出现进行性呼吸困难和低氧血症,伴弥漫性支气管痉挛。紧急胸部 X 线检查结果正常。给予患者吸氧和吸入及静脉用类固醇治疗,但仅在给予静脉用氨茶碱后呼吸困难和支气管痉挛才得以缓解。心律失常再次发作,最终给予静脉用氟卡尼终止。尽管腺苷给药后出现呼吸困难通常是短暂的、良性现象,但医生应警惕存在呼吸窘迫的客观体征,即使在无既往肺部疾病史的患者中,也应立即进行治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验